170 related articles for article (PubMed ID: 34984839)
1. Results from a multicenter, randomized, double-blind, placebo-controlled study of repository corticotropin injection for multiple sclerosis relapse that did not adequately respond to corticosteroids.
Wynn D; Goldstick L; Bauer W; Zhao E; Tarau E; Cohen JA; Robertson D; Miller A
CNS Neurosci Ther; 2022 Mar; 28(3):364-371. PubMed ID: 34984839
[TBL] [Abstract][Full Text] [Related]
2. A Prospective Observational Registry of Repository Corticotropin Injection (Acthar® Gel) for the Treatment of Multiple Sclerosis Relapse.
Kaplan J; Miller T; Baker M; Due B; Zhao E
Front Neurol; 2020; 11():598496. PubMed ID: 33414758
[No Abstract] [Full Text] [Related]
3. Results From a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis.
Mirsaeidi M; Baughman RP; Sahoo D; Tarau E
Pulm Ther; 2023 Jun; 9(2):237-253. PubMed ID: 37072607
[TBL] [Abstract][Full Text] [Related]
4. Repository corticotropin injection improves quality metrics in an observational study of multiple sclerosis relapse.
Kaplan J; Miller T; Baker M; Due B; Zhao E
Neurodegener Dis Manag; 2021 Dec; 11(6):469-476. PubMed ID: 34860120
[TBL] [Abstract][Full Text] [Related]
5. Acthar Gel (repository corticotropin injection) for persistently active SLE: study design and baseline characteristics from a multicentre, randomised, double-blind, placebo-controlled trial.
Askanase AD; Zhao E; Zhu J; Connolly-Strong E; Furie RA
Lupus Sci Med; 2020; 7(1):e000383. PubMed ID: 32399253
[TBL] [Abstract][Full Text] [Related]
6. Repository corticotropin injection versus corticosteroids for protection against renal damage in a focal segmental glomerulosclerosis rodent model.
Hayes K; Warner E; Bollinger C; Wright D; Fitch RM
BMC Nephrol; 2020 Jun; 21(1):226. PubMed ID: 32539845
[TBL] [Abstract][Full Text] [Related]
7. Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
Askanase AD; Zhao E; Zhu J; Bilyk R; Furie RA
Rheumatol Ther; 2020 Dec; 7(4):893-908. PubMed ID: 32996096
[TBL] [Abstract][Full Text] [Related]
8. Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar
Askanase AD; Wan GJ; Panaccio MP; Zhao E; Zhu J; Bilyk R; Furie RA
Rheumatol Ther; 2021 Mar; 8(1):573-584. PubMed ID: 33687687
[TBL] [Abstract][Full Text] [Related]
9. Clinical and Economic Evaluation of Repository Corticotropin Injection: A Narrative Literature Review of Treatment Efficacy and Healthcare Resource Utilization for Seven Key Indications.
Philbin M; Niewoehner J; Wan GJ
Adv Ther; 2017 Aug; 34(8):1775-1790. PubMed ID: 28660550
[TBL] [Abstract][Full Text] [Related]
10. Acthar Gel (RCI): A Narrative Literature Review of Clinical and Economic Evidence.
Wan GJ; Niewoehner J; Hayes K
Clinicoecon Outcomes Res; 2023; 15():499-512. PubMed ID: 37397803
[TBL] [Abstract][Full Text] [Related]
11. Post Hoc Biomarker Analyses from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus.
Askanase AD; Wright D; Zhao E; Zhu J; Bilyk R; Furie RA
Rheumatol Ther; 2021 Dec; 8(4):1871-1886. PubMed ID: 34478124
[TBL] [Abstract][Full Text] [Related]
12. Consequences of Insurance Denials Among U.S. Patients Prescribed Repository Corticotropin Injection for Acute Exacerbations of Multiple Sclerosis.
Rice JB; Panaccio MP; White A; Simes M; Billmyer E; Downes N; Niewoehner J; Wan GJ
Neurol Ther; 2021 Jun; 10(1):149-167. PubMed ID: 33170434
[TBL] [Abstract][Full Text] [Related]
13. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the Clinical Evidence Supporting Repository Corticotropin Injection for FDA-Approved Indications: A Scoping Review.
Tran KA; Harrod C; Bourdette DN; Cohen DM; Deodhar AA; Hartung DM
JAMA Intern Med; 2022 Feb; 182(2):206-217. PubMed ID: 34902005
[TBL] [Abstract][Full Text] [Related]
15. A Narrative Review of Repository Corticotropin Injection for the Treatment of Systemic Lupus Erythematosus.
Askanase AD; Furie RA
Adv Ther; 2022 Jul; 39(7):3088-3103. PubMed ID: 35641860
[TBL] [Abstract][Full Text] [Related]
16. Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis: A Narrative Review.
Mirsaeidi M; Baughman RP
Pulm Ther; 2022 Mar; 8(1):43-55. PubMed ID: 35113366
[TBL] [Abstract][Full Text] [Related]
17. Real-world treatment patterns for repository corticotropin injection in patients with rheumatoid arthritis.
Busch H; Wan GJ; Niewoehner J; Houston P; Su Y; Clinton C; Panaccio MP
Drugs Context; 2022; 11():. PubMed ID: 35382109
[TBL] [Abstract][Full Text] [Related]
18. Repository Corticotropin Injection (Acthar
Wirta D; McLaurin E; Ousler G; Liu J; Kacmaz RO; Grieco J
Ophthalmol Ther; 2021 Dec; 10(4):1077-1092. PubMed ID: 34669183
[TBL] [Abstract][Full Text] [Related]
19. A Systematic Literature Review and Indirect Treatment Comparison of Efficacy of Repository Corticotropin Injection versus Synthetic Adrenocorticotropic Hormone for Infantile Spasms.
Duchowny MS; Chopra I; Niewoehner J; Wan GJ; Devine B
J Health Econ Outcomes Res; 2021 Jan; 8(1):1-9. PubMed ID: 33521161
[No Abstract] [Full Text] [Related]
20. Acthar® Gel (repository corticotropin injection) dose-response relationships in an animal model of epileptic spasms.
Le JT; Frost JD; Swann JW
Epilepsy Behav; 2021 Mar; 116():107786. PubMed ID: 33548914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
